A further $173 billion a year is real on paper – but only once three separate regulatory clocks finish running down.
Resolution Therapeutics has treated its last EMERALD trial patient, putting macrophage-based therapy on track for results ...
Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same ...
Inside the $230 billion our new Longevity Biotech Report says the pipeline is already worth – no regulatory rewrite required.
Telomir’s oncology compound helped fish with age-related retinal damage see better and moved two aging-linked markers toward ...
Enveda raised $311 million to push its AI-discovered medicines forward, including one aimed at life after GLP-1 drugs.
Phil Newman analyzes Oura’s IPO and lawsuit, movement context in dementia, GenFlow dog trial, Rentosertib aging clocks, and ...
A new connector lets Function Health members bring lab results and biomarker trends straight into Meta’s personal AI agent, ...
Belgian clinical data show Allegro’s nanotech injection Hydrocelin delivers lasting knee osteoarthritis relief from a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results